J&J beats profit estimates, lifts outlook on pharma unit strength
Johnson & Johnson reported slightly better-than-expected third-quarter 2018 profit and raised the company’s full-year forecast.
Featured Posts
Pharma Innovators Special Feature 2018: Focus on innovation
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
2015 U.S. trends in aggregate spend, disclosure, and transparency
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
One Drop’s Apple Watch App Points to Trend in Wearable Health Devices
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.
Electrode treatment, physical therapy combination lets two paralyzed people walk again
Doctors in Kentucky reported that two of four paralyzed patients were able to walk again with limited assistance after treatment with electrical stimulation to the portion of the spinal cord cut off from the brain, combined with intense physical therapy.
Boston Scientific drug-coated stent gets FDA approval
The U.S. Food and Drug Administration approved Boston Scientific Corp.’s drug-coated stent Eluvia to treat narrowed arteries in the leg.
Zealand Pharma’s Phase III Severe Hypoglycemia Rescue Treatment Hits the Mark in Clinical Trial
Denmark-based Zealand Pharma announced that the company’s Phase III trial for dasiglucagon for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints, setting up potential regulatory approval.
FDA and FCB Launch First National Youth Vaping Education Campaign
FCB New York, in partnership with the Food and Drug Administration, announced that the agency launched the newest evolution of “The Real Cost” youth tobacco prevention campaign.
Consort, Opiant to develop nasal spray for opioid overdose treatment
Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.
J&J to work with India on compensation for recalled hip implants
Johnson & Johnson said the company would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.
Walgreens to supply Kaleo’s allergy shots as EpiPen shortage drags
Walgreens Boots Alliance Inc. said emergency allergy shots from Kaleo will be available in the U.S. drugstore chain’s stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season.
Indian panel wants Johnson & Johnson to pay compensation over recalled implants
A government panel recommended that Johnson & Johnson pay compensation of at least $28,500 to each Indian patient who suffered from artificial hip implants the U.S. healthcare firm recalled eight years ago.
Novartis says glaucoma stent setback will not derail Alcon spin-off
Novartis’ eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit 2019.
AstraZeneca inhaler lags GSK drug in lung disease trial
A new AstraZeneca inhaler for chronic lung disease proved worse than a rival GlaxoSmithKline product in a clinical trial.
FDA Clears SPR Therapeutics’ Non-Opioid Neurostimulation Pain Therapies
The U.S. Food and Drug Administration cleared Cleveland-based SPR Therapeutics’ SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems for controlling pain.
Pharma Innovators Special Feature 2018: Focus on innovation
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
FCB Health Network’s 2018 Next: Innovation Week conference
For the second year, FCB Health Network brought together a stellar group of experts to showcase the latest offerings in virtual and augmented reality, social media, technology, hardware, artificial intelligence, cloud computing services, data visualization, design, and more for its Next: Innovation Week series.
Boston Scientific Continues M&A Spree
Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.
Breast Cancer Device Receives FDA Approval
The U.S. Food and Drug Administration approved the first non-radioactive, dual-tracer for sentinel lymph node biopsy.
Bayer hits back at new Netflix medical device documentary
Bayer AG disputed accusations in a new Netflix documentary that claims medical device makers and the U.S. Food and Drug Administration placed profits before patient safety.
U.S. House Votes to Repeal Medical Device Tax, Goes Before Senate
After multiple suspensions, the U.S. House of Representatives overwhelmingly voted to repeal a 2.3 percent tax on medical devices which is part of the Affordable Care Act that industry representatives believes has stifled innovation.
Bayer to phase out Essure birth control device in U.S.
Bayer will discontinue the sale of the healthcare company’s birth control product Essure in the United States.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!